Efficacy and Safety Study of GM602 in Patients With Acute Middle Cerebral Artery Ischemic Stroke Within 18 Hours (GMAIS)
A Phase 2 Double Blinded, Randomized, Placebo Controlled Dose Escalation Study to Evaluate the Efficacy and the Safety of GM602 in Patients With Acute Middle Cerebral Artery Ischemic Stroke Within an 18-hour Treatment Window
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
California
-
Los Angeles, California, United States, 90095
- UCLA Stroke Center (Departments of Emergency Medicine and Neurology at the University of California, Los Angeles Medical Center)
-
Newport Beach, California, United States, 92658
- Hoag Memorial Hospital Presbyterian
-
Pasadena, California, United States, 91105
- Huntington Memorial Hospital Stroke Center
-
San Francisco, California, United States, 94107
- California Pacific Medical Center Research Institute
-
-
Florida
-
Sarasota, Florida, United States, 34239
- Sarasota Memorial Hospital
-
-
Kentucky
-
Louisville, Kentucky, United States, 40202
- University of Louisville
-
-
New York
-
New York, New York, United States, 10032
- Columbia University Medical Center
-
-
Tennessee
-
Chattanooga, Tennessee, United States, 37403
- University Erlanger Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- > 18 years old
- Be eligible for MRI or CT scan
- Have suffered acute ischemic stroke in the middle cerebral artery (MCA) distribution, as verified by the Screening diffusion-weighted imaging (DWI) abnormality and Screening perfusion-weighted imaging pressure-work index (PWI ) abnormality
- Have NIH Stroke Scale (NIHSS) score total score of 9-20 inclusive at screening
- Have suffered acute ischemic stroke within 18 hours
- Have been functionally independent with a Modified Rankin Score (mRS) of 0 or 1 prior to suffering stroke
- Patients who received tPA or FDA approved mechanical device can also enroll
- completed informed consent form
Exclusion Criteria:
- Have history of stroke in the past 3 months
- Cannot be evaluated using MRI/CT
- Have stroke of the brainstem or cerebellum
- Have clinical presentation consistent with acute MI by EKG criteria (STEMI) at screening
- Have hemorrhage revealed by CT or MRI scan
- Have > 1/3 MCA territory HYPER intensity as seen on MRI OR >1/3 MCA territory HYPO intensity as seen on CT
- Have blood sugar level >400 mg/DL or<50 mg/dL
- Have kidney disease, creatinine > 2.0
- Have had recent (within 90 days) serious head trauma or head trauma with loss of consciousness
- Have any prior history of seizure
- Have clinically relevant pre-existing neurological deficit (Historical Rankin score ≥ 2)
- Have any other known clinically significant medical disorder (cardiovascular, hepatic, renal, endocrine, respiratory, immunological, cancer, AIDS)
- Life expectancy of less than 6 months due to comorbid conditions
- Women of child bearing potential who are pregnant or breast-feeding or unable to practice birth control during the study period
- Have participated in any other trial of an investigational agent within 90 days prior to screening
- Informed consent cannot be obtained
- Unable to participate in study visits
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: GM602
First 9 moderate patients (either co-treated or not co-treated) will be randomized to receive 320 mg/dose of GM602 or placebo in a 2:1 ratio, then the next 9 moderate patients (either co-treated or not co-treated) will be randomized to receive 480 mg/dose of GM602 or placebo in a 2:1 ratio.
Concurrently, 18 severe patients will be randomized in the same manner.
Total 12 moderate and 12 severe patients will receive GM602.
|
First 9 moderate patients (either co-treated or not co-treated) will be randomized to receive 320 mg/dose of GM602 or placebo in a 2:1 ratio, then the next 9 moderate patients (either co-treated or not co-treated) will be randomized to receive 480 mg/dose of GM602 or placebo in a 2:1 ratio.
Concurrently, 18 severe patients will be randomized in the same manner.
Total 12 moderate and 12 severe patients will receive GM602.
Other Names:
|
|
Placebo Comparator: Placebo Comparator
First 9 moderate patients (either co-treated or not co-treated) will be randomized to receive 320 mg/dose of GM602 or placebo in a 2:1 ratio; then the next 9 moderate patients (either co-treated or not co-treated) will be randomized to receive 480 mg/dose of GM602 or placebo in a 2:1 ratio.
Concurrently, 18 severe patients will be randomized in the same manner.
Total 6 moderate and 6 severe patients receive Placebo.
|
First 9 moderate patients (either co-treated or not co-treated) will be randomized to receive 320 mg/dose of GM602 or Matching Placebo (Bacteriostatic Saline) for GM602 in a 2:1 ratio, then the next 9 moderate patients (either co-treated or not co-treated) will be randomized to receive 480 mg/dose of GM602 or placebo in a 2:1 ratio.
Concurrently, 18 severe patients will be randomized in the same manner.
Total 6 moderate and 6 severe patients will receive placebo.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Functional Outcome as measured by the difference in percent change in NIHSS from baseline to 90 days in patients treated with GM602 within 18 hours compared to treated with placebo as primary efficacy endpoint
Time Frame: Day 90
|
NIH Stroke Scale is a standardized neurological examination intended to describe the neurological deficits found in large groups of stroke patients participating in treatment trials.
Percent change from baseline in NIHSS is calculated and compared.
|
Day 90
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Functional Outcome as measured by the difference in percent change in NIHSS from baseline to 30 days in patients treated with GM602 compared to treated with placebo
Time Frame: Day 30
|
Percent change in NIHSS from baseline to 30 days in patients treated with any active dose of GM602 compared with placebo
|
Day 30
|
|
Percent change in Barthel Index (BI) from baseline to 90 days in patients treated with GM602 compared to treated with placebo
Time Frame: Day 90
|
The Barthel Index is measured using both historical and direct observational information.
It measures self-care and mobility and will help define the degree of residual disability.
Percent change from baseline in BI is calculated.
|
Day 90
|
|
Percent change in Barthel Index (BI) from baseline to 30 days in patients treated with GM602 compared to treated with placebo
Time Frame: Day 30
|
Percent change in BI from baseline to 30 days in patients treated with any active dose of GM602 compared with placebo
|
Day 30
|
|
Proportion of patients treated with any active dose of GM602 compared with placebo at each mRS level at 90 days
Time Frame: Day 90
|
compared with placebo at each modified Rankin Scale (mRS) level at 90 days.
|
Day 90
|
|
Proportion of patients treated with any active dose of GM602 compared with placebo at each mRS level at 30 days
Time Frame: Day 30
|
compared with placebo at each modified Rankin Scale (mRS) level at 30 days.
|
Day 30
|
|
Secondary safety endpoint as measured by all cause mortality data through 3 months for patients treated with GM602 compared with placebo
Time Frame: Day 90
|
all cause mortality data through 3 months
|
Day 90
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Primary Safety Endpoints
Time Frame: througyh 3 months
|
Adverse events, Fatal intracranial hemorrhage (ICH).
nonfatal symptomatic parenchymal hemorrhage, or other symptomatic ICH, Neurological deterioration during hospitalization, Number of seizures after stroke, Respiratory compromise as observed by respiratory rate
|
througyh 3 months
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Arbi G Ohanian, MD, Huntington Memorial Hospital
- Principal Investigator: Sidney Starkman, MD, UCLA Stroke Center
- Principal Investigator: Jeff Saver, MD, UCLA Stroke Center
- Principal Investigator: David Brown, MD, Hoag Memorial Hospital Presbyterian
- Principal Investigator: Stephan A Mayer, M.D., Columbia University
- Principal Investigator: Nobl Barazangi, M.D., California Pacific Medical Center Research Institute
- Principal Investigator: Thomas G Devlin, M.D., University Erlanger Hospital
- Principal Investigator: Mauricio Concha, M.D., Sarasota Memorial Hospital
- Principal Investigator: Anand Vaishnav, M.D., University of Louisville
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- GEN-002
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.